Quality of life and psychological well-being in Spanish long-term survivors of Hodgkin's disease: results of a controlled pilot

Complutense University of Madrid, Madrid, Madrid, Spain
Annals of Hematology (Impact Factor: 2.63). 02/2003; 82(1):14-8. DOI: 10.1007/s00277-002-0582-0
Source: PubMed


Nowadays, the chemoradiotherapeutic protocols for Hodgkin's disease (HD) achieve high curability rates. Hemato-oncologists focus on both avoiding medical and psychological sequelae of the treatment and returning patients to a normal life. The quality of life and psychological well-being of Spanish patients who are long-term survivors of HD were studied and compared to the results obtained from healthy controls. Questionnaires on quality of life [European Organization for Research and Treatment of Cancer (EORTC) QLQ30] and psychological status [hospital anxiety and depression (HAD) scale] were mailed to HD patients without active disease and free of second malignancies and were also given to healthy controls. Of 67 selected patients (68.6%), 46 were included in this study. The median follow-up for these 46 patients was of 7.6 years (0.8-22.1) after being diagnosed. Although there were no differences between patients and controls with regard to their global state of health and quality of life (72.9+/-22.7 vs 79.3+/-18.7; p=0.22), patients presented a lower physical function (88.2+/-18.1 vs 96.5+/-9.7; p=0.05) and a worse social operation scale (81.5+/-25.4 vs 96.3+/-13.1; p= 0.0015) together with higher symptoms of dyspnea (8.6+/-14.7 vs 0+/-0; p=0.03) and higher economic difficulties (23.1+/-38.3 vs 0.7+/-4.9; p=0.017) when compared with healthy controls. However, we did not find differences in the scores and the proportion of cases of anxiety and depression between the two groups. The quality of life questionnaire disclosed differences between patients and controls in some functional and symptomatic scales. These differences can be read as a consequence of either the disease itself or the treatment received. However, the results of this controlled pilot study should be confirmed in a larger series of Spanish HD survivors. In the future, these results could be a reference when new therapeutic protocols are designed to reduce the impact on the quality of life of the patients. Socioeconomic support to the patients should also be provided in order to improve their medical care.

5 Reads
  • Source
    • "Five studies found that HL survivors had clinically important lower scores on social functioning compared to normative samples [9, 15, 22, 24, 26]. Three studies found no clinically important differences on social functioning [27, 28, 30]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer survivors are at risk of experiencing adverse physical and psychosocial effects of their cancer and its treatment. Both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) survivors face problems that can affect their health-related quality of life (HRQoL). The authors systematically reviewed the literature on HRQoL among HL and NHL survivors. A PubMed and PsychINFO literature search for original articles published until May 2011 was performed. Twenty-four articles, which met the predefined inclusion criteria, were subjected to a quality checklist. HL survivors showed the most problems in (role) physical, social and cognitive functioning, general health, fatigue and financial problems. In addition, HL survivors treated with a combination of therapies, with older age and female sex reported worse HRQoL. NHL survivors showed the most problems in physical functioning, appetite loss, vitality and financial problems. Having had chemotherapy was negatively associated with HRQoL, but no differences in chemotherapy regimens were found. Furthermore, in NHL survivors not meeting public exercise guidelines, HRQoL is low but can be improved with more exercise. More research on the longitudinal comparison between HL and NHL survivors and healthy controls should be performed in order to better understand the long-term (side) effects of treatment on HRQoL and possibilities to alleviate these.
    Annals of Hematology 06/2011; 90(9):993-1004. DOI:10.1007/s00277-011-1274-4 · 2.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in the treatment of haematological malignancies have greatly contributed to increased survival rates and improved prognosis. Patients, however, generally experience a great number of debilitating symptoms (e.g. fatigue, nausea, pain and depression) and impaired function affecting their quality of life (QOL). Besides sex differences in survival, there is evidence that disease affects facets of life differently in men and women. Literature indicates significantly better physical, emotional as well as role functioning in male haemato-oncological patients and suggests female gender to be a predictor of impaired overall QOL. Possible explanations comprise differences in biological features, gender-specific behaviour and measurement bias. Clinical implications point toward increased awareness for disease- and treatment-related aspects especially relevant in either male or female patients. Already evident gender patterns found in the perception of pain, communication styles and role limitations should be considered in the development and application of medical as well as psychosocial interventions.
    memo - Magazine of European Medical Oncology 12/2012; 4(4). DOI:10.1007/s12254-011-0299-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: The first attempts to treat Hodgkin’s disease by radiotherapy were conducted at the beginning of the last century. The prognosis for survival was poor but slowly improved by the use of radiotherapy and some chemotherapy until 1960. For example, in 1939 a 20-year survival rate of 17% was reported.1
    01/1970: pages 90-100;
Show more